Author: Customer Service

The Board of Director of Tivoli A/S has adopted the Interim Report for the period 1 January – 30 June 2025.   Tivoli opened the summer season on the 4 April, which is later than last year, where the season opened on the 22 March. This affects the result for the period, as outlined: A revenue of DKK of 445.0 million compared to DKK 455.3 million last year (-2%).  An EBITDA of DKK -17.8 million compared to DKK -6.3 million last year.  A profit before tax of DKK -76.1 million compared to DKK -63.5 million last year.  An attendance figure of 1,325,000 visitors compared to 1,391,000 last year (-5%). ”Tivoli experienced a great summer season marked by numerous highlights and well-attended events. The summer season commenced on April 4, two weeks later than in 2024 due to a later Easter. The summer was characterized by forecasts of unstable...

07:00 London, 09:00 Helsinki, 15 August 2025 – Afarak Group SE (“Afarak” or “the Company”) (LSE: AFRK, NASDAQ: AFAGR) FINANCIAL INTERIM RELEASE H1 2025    H1/25 H1/ 24 2024Revenue EUR million 77.1 71.4 128.6EBITDA EUR million 6.9 4.2 2.6EBIT EUR million 5.9 3.1 -0.1Earnings before taxes EUR million 3.4 1.9 -5.3Profit EUR million 2.4 0.5 -7.2Earnings per share EUR 0.01 0.00 -0.03EBITDA margin   9.0% 5.9% 2.0%EBIT margin   7.7% 4.3% -0.1%Earnings margin   4.5% 2.6% -4.1%Personnel (end of period)   613 588 602                  FIRST HALF 2025 HIGHLIGHTSRevenue increased by 8% to EUR 77.1 (H1/2024: 71.4) million; Afarak successfully completed the sale of its Ilitha and Zeerust mining assets in South Africa, generating a gain of EUR 2.4 million; Processed material sold...

Oslo, Norway, 15th of August 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the second quarter of 2025. Revenue in the second quarter ended at MNOK 118 compared to MNOK 106 in Q2 2024. The increase in revenue was driven by 17% higher sales volume. Revenue for first half of 2025 ended at MNOK 233 compared to MNOK 210 YTD last year, an increase of 11%. Second quarter EBITDA ended at MNOK 30 compared to MNOK 27 in Q2 2024, representing 11% increase. EBITDA was positively affected by increased sales volume and continued focus on cost improvements. EBITDA for first half of 2025 ended at MNOK 60 compared to MNOK 48 YTD 2024, an increase of 27%. The net profit ended at MNOK 40.2 (26.8) for the first half of 2025. Cash dividend of NOK 1.25 per share distributed to shareholders in June. The second quarter conference call,...

Friday, Schouw & Co. released its interim report for the second quarter of 2025; Schouw & Co. delivered an overall Q2 2025 performance in line with expectations where the portfolio companies have taken strong measures to mitigate global market changes.  HighlightsDKK 8.5bn revenue – a 2% decrease DKK 706m EBITDA – a 4% decrease DKK 542m cash flow from operations – a 61% improvement DKK 10.18 earnings per share – a 3% decrease 12.5% ROIC excluding goodwill – a 1.3 pp decrease Full-year revenue and EBITDA guidance narrowed within previous range.Statement by Jens Bjerg Sørensen, President of Schouw & Co. – Schouw & Co. experienced a challenging yet stable second quarter of 2025, with consolidated revenue and EBITDA slightly down on the second quarter of 2024. The diversified portfolio provided stability amid global...

August 15, 2025Announcement no. 19 BioPorto Interim Result for the Second Quarter of 2025 – Continued progress with full execution of strategic objectives and strong NGAL sales growth. Copenhagen, Denmark, August 15, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), today announced interim financial results for the second quarter of 2025 and a business update. Continued progress on key strategic milestones for the second quarter of 2025Full execution of the objectives outlined in our February 2024 Strategic Plan. A major milestone in the second quarter of 2025 was the receipt of the first purchase order for ProNephroTM AKI (NGAL) for the US market, marking the first step in the commercial launch. The enrollment of patients in the US clinical cut-off study for ProNephro AKI (NGAL) for adult use...

FINANCIAL HIGHLIGHTSIn Q2 2025, Pandora continued to deliver solid revenue growth and margins despite the increasingly turbulent macroeconomic backdrop as well as headwind from foreign exchange, tariffs and commodity prices. Q2 2025 organic growth ended at 8%. Like-for-like (LFL) was 3% and network expansion added 5% to growth. LFL growth in the US remained strong at 8%, and Rest of Pandora was robust at 6%. Despite some challenges in the four European markets disclosed separately, overall LFL in Europe was 1% fuelled by double-digit growth in several countries, including for example Spain, Portugal, the Netherlands and Poland. The gross margin remained strong at 79.3% despite 170bp headwind from foreign exchange, commodities and tariffs (80.2% in Q2 2024). Pricing and cost efficiencies continued to contribute positively.   The Q2...